Artgen Fair Value
AB
The fair market value of ABIO.ME stock is 202.32 RUB. Relative to the market price of 75.5 RUB Artgen Biotech is undervalued by 168%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Artgen Valuation
Current ABIO.ME share ticker price is 75.5 RUB.
The fair value level of 202.32 RUB can be considered as an effective entry point for long-term investors to start investing in ABIO.ME stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 168% lower its fair value
Current price is 42% higher its minimum value
Current price is 813% lower its maximum value
Market price:
ABIO.ME stock is undervalued
It means the current price may concern as a Moderate Risk Entry Point
Artgen Biotech Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
290.2
2
Median P/E over 5 years
85.17
3
Minimum P/E over 5 years
18.33
4
Earning per share (last 12 months)
2.38 RUB
Maximum value
1
x
4
=
689.34 RUB
Fair value
2
x
4
=
202.32 RUB
Minimum value
3
x
4
=
43.54 RUB
Artgen Biotech price metrics
37.4
Annual return (geometric mean)
69.4
Risk (standard deviation) of returns
β
-0.1
Beta (volatility compared to market)